Free Trial
NASDAQ:CRIS

Curis (CRIS) Stock Price, News & Analysis

Curis logo
$1.58 +0.06 (+3.95%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Curis Stock (NASDAQ:CRIS)

Advanced

Key Stats

Today's Range
$1.52
$1.60
50-Day Range
$1.45
$1.83
52-Week Range
$1.02
$5.45
Volume
47,182 shs
Average Volume
95,938 shs
Market Capitalization
$19.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00
Consensus Rating
Hold

Company Overview

Curis Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
45th Percentile Overall Score

CRIS MarketRank™: 

Curis scored higher than 45% of companies evaluated by MarketBeat, and ranked 606th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Curis has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.

  • Upside Potential

    Curis has a consensus price target of $17.00, representing about 983.5% upside from its current price of $1.57.

  • Amount of Analyst Coverage

    Curis has only been the subject of 1 research reports in the past 90 days.

  • Read more about Curis' stock forecast and price target.
  • Earnings Growth

    Earnings for Curis are expected to grow in the coming year, from ($7.12) to ($3.49) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Curis is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Curis is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Curis' valuation and earnings.
  • Percentage of Shares Shorted

    1.33% of the float of Curis has been sold short.
  • Short Interest Ratio / Days to Cover

    Curis has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Curis has recently decreased by 2.02%, indicating that investor sentiment is improving.
  • Dividend Yield

    Curis does not currently pay a dividend.

  • Dividend Growth

    Curis does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.33% of the float of Curis has been sold short.
  • Short Interest Ratio / Days to Cover

    Curis has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Curis has recently decreased by 2.02%, indicating that investor sentiment is improving.
  • News Sentiment

    Curis has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Curis this week, compared to 1 article on an average week.
  • Search Interest

    4 people have searched for CRIS on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Curis to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Curis insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.45% of the stock of Curis is held by insiders.

  • Percentage Held by Institutions

    Only 29.97% of the stock of Curis is held by institutions.

  • Read more about Curis' insider trading history.
Receive CRIS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Curis and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CRIS Stock News Headlines

The Final Displacement
A new documentary called The Final Displacement is stirring major controversy — and for good reason. It exposes an unstoppable economic force that could devastate millions of Americans financially while creating massive new wealth for others. Goldman Sachs estimates more than 12,000 people a day are already being affected. You deserve to see what’s really happening before it accelerates.tc pixel
See More Headlines

CRIS Stock Analysis - Frequently Asked Questions

Curis' stock was trading at $3.06 at the start of the year. Since then, CRIS stock has decreased by 48.7% and is now trading at $1.5690.

Curis, Inc. (NASDAQ:CRIS) released its quarterly earnings results on Tuesday, August, 5th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating analysts' consensus estimates of ($1.99) by $1.31. The biotechnology company earned $2.75 million during the quarter, compared to analysts' expectations of $2.64 million.
Read the conference call transcript
.

Curis's stock reverse split on the morning of Friday, September 29th 2023.The 1-20 reverse split was announced on Friday, September 29th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Top institutional shareholders of Curis include Focused Wealth Management Inc (0.63%).
View institutional ownership trends
.

Shares of CRIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Curis investors own include Micron Technology (MU), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), NIO (NIO), Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
8/05/2025
Today
10/16/2025
Next Earnings (Estimated)
11/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CRIS
CIK
1108205
Employees
60
Year Founded
2000

Price Target and Rating

High Price Target
$17.00
Low Price Target
$17.00
Potential Upside/Downside
+986.3%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.88)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$43.39 million
Net Margins
-341.24%
Pretax Margin
-341.24%
Return on Equity
N/A
Return on Assets
-102.22%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.74
Quick Ratio
0.74

Sales & Book Value

Annual Sales
$10.91 million
Price / Sales
1.79
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.71) per share
Price / Book
-2.20

Miscellaneous

Outstanding Shares
12,500,000
Free Float
11,818,000
Market Cap
$19.56 million
Optionable
No Data
Beta
3.86

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:CRIS) was last updated on 10/16/2025 by MarketBeat.com Staff
From Our Partners